

Supplementary Table S1: Correlation between PD-1 expression and clinicopathological characteristics in AGC patients.

Clinicopathological features	Cases	PD-1 expression		P-value(χ^2 test)
		High 58	Low 451	
Gender				
Male	347	43	304	0.3002
Female	162	15	147	
Age(years)				
≤60	224	25	199	0.8828
> 60	285	33	252	
Tumor location				
Up	73	8	65	0.5121
Middle	105	8	97	
Low	260	35	225	
Total	66	7	59	
Remnant	5	0	5	
Length-diameter				
< 5cm	232	22	210	0.2141
≥5cm	277	36	241	
Lauren type				
Intestinal	163	13	150	0.2392
Diffuse	326	42	284	
Mix	20	3	17	
Blood-vessel invasion				
absent	413	43	370	0.1476
present	96	15	81	
Perineuronal invasion				
absent	429	43	386	0.0241*
present	80	15	65	
pT stage				
T2	85	10	75	0.8254
T3	151	19	132	
T4	273	29	244	
pN stage				
N0	162	17	145	0.9415
N1	96	12	84	
N2	112	12	100	
N3	139	17	122	
TNM stage				
I	49	4	45	0.7542
II	172	20	152	
III	288	34	254	

* : $P < 0.05$, ** : $P < 0.01$;

Supplementary Table S2: Correlation between CD3 expression and clinicopathological characteristics in AGC patients.

Clinicopathological features	Cases	CD3 expression		P-value(χ^2 test)
		High 254	Low 255	
Gender				
Male	347	173	174	0.9758
Female	162	81	81	
Age(years)				
≤60	224	121	103	0.0996
> 60	285	133	152	
Tumor location				
Up	73	41	32	0.2202
Middle	105	43	62	
Low	260	131	129	
Total	66	37	29	
Remnant	5	2	3	
Length-diameter				
< 5cm	232	117	115	0.8907
≥5cm	277	138	139	
Lauren type				
Intestinal	163	67	96	0.0243*
Diffuse	326	176	150	
Mix	20	11	9	
Blood-vessel invasion				
absent	413	206	207	0.9830
present	96	48	48	
Perineuronal invasion				
absent	429	214	215	0.9847
present	80	40	40	
pT stage				
T2	85	41	44	0.9445
T3	151	76	75	
T4	273	137	136	
pN stage				
N0	162	75	87	0.3927
N1	96	55	41	
N2	112	56	56	
N3	139	68	71	
TNM stage				
I	49	21	28	0.5837
II	172	87	85	
III	288	146	142	

* : $P < 0.05$, ** : $P < 0.01$;

Supplementary Table S3: Correlation between CD8 expression and clinicopathological characteristics in AGC patients.

Clinicopathological features	Cases	CD8 expression		P-value(χ^2 test)
		High 254	Low 255	
Gender				
Male	347	173	174	0.9758
Female	162	81	81	
Age(years)				
≤60	224	114	110	0.6918
> 60	285	140	145	
Tumor location				
Up	73	44	29	0.0859
Middle	105	45	60	
Low	260	124	136	
Total	66	39	27	
Remnant	5	2	3	
Length-diameter				
< 5cm	232	112	120	0.5020
≥5cm	277	142	135	
Lauren type				
Intestinal	163	71	92	0.1171
Diffuse	326	171	155	
Mix	20	12	8	
Blood-vessel invasion				
absent	413	211	202	0.2663
present	96	43	53	
Perineuronal invasion				
absent	429	211	218	0.4534
present	80	43	37	
pT stage				
T2	85	36	49	0.3008
T3	151	79	72	
T4	273	139	134	
pN stage				
N0	162	84	78	0.0242*
N1	96	59	37	
N2	112	46	66	
N3	139	65	74	
TNM stage				
I	49	21	28	0.3073
II	172	93	79	
III	288	140	148	

* : $P < 0.05$, ** : $P < 0.01$;

Supplementary Table S4: Correlation between FOXP3 expression and clinicopathological characteristics in AGC patients.

Clinicopathological features	Cases	FOXP3 expression		P-value(χ^2 test)
		High 97	Low 412	
Gender				
Male	347	71	276	0.2378
Female	162	26	136	
Age(years)				
≤60	224	38	186	0.2865
> 60	285	59	226	
Tumor location				
Up	73	10	63	0.3760
Middle	105	19	86	
Low	260	57	203	
Total	66	11	55	
Remnant	5	0	5	
Length-diameter				
< 5cm	232	49	183	0.2780
≥5cm	277	48	229	
Lauren type				
Intestinal	163	26	137	0.3831
Diffuse	326	68	258	
Mix	20	3	17	
Blood-vessel invasion				
absent	413	80	333	0.7088
present	96	17	79	
Perineuronal invasion				
absent	429	82	347	0.9393
present	80	15	65	
pT stage				
T2	85	17	68	0.9626
T3	151	29	122	
T4	273	51	222	
pN stage				
N0	162	35	127	0.8005
N1	96	17	79	
N2	112	20	92	
N3	139	25	114	
TNM stage				
I	49	12	37	0.5844
II	172	31	141	
III	288	54	234	

* : $P < 0.05$, ** : $P < 0.01$;